← Back to Clinical Trials
Recruiting NCT04556019

NCT04556019 Results of Surgical Treatment of the Hepatobiliopancreatic Surgical Unit

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04556019
Status Recruiting
Phase
Sponsor Fundacion Miguel Servet
Condition Pancreas Disease
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2019-01-03
Primary Completion 2024-01

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
Hepatobiliopancreatic surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2019-01-03 with a primary completion date of 2024-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main aims of this study are: 1. \- to evaluate post-surgical morbidity and mortality outcomes, following the criteria and the definitions from Claven-Dindo and ISGPS international classifications, of the patients operated by the HPB Surgical Unit. 2. \- to evaluate survival and disease-free survival rates of the patients operated by the HPB Surgical Unit due to tumoral cause.

Eligibility Criteria

Inclusion Criteria: * All patients operated by the HPB Surgical Unit in the last 10 years (retrospective) * All patients being operated by the HPB Surgical Unit from January 2019 onwards who provide inform consent (prospective). Exclusion Criteria: * Patients not eligible for surgery * Patients not interested in taking part in the study

Contact & Investigator

Central Contact

Francisco Javier Herrera Cabezón, MD

✉ javier.herrera.cabezon@cfnavarra.es

📞 0034 848422187

Principal Investigator

Francisco Javier Herrera Cabezón, MD

PRINCIPAL INVESTIGATOR

Complejo Hospitalario de Navarra

Frequently Asked Questions

Who can join the NCT04556019 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, up to 90 Years, studying Pancreas Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04556019 currently recruiting?

Yes, NCT04556019 is actively recruiting participants. Contact the research team at javier.herrera.cabezon@cfnavarra.es for enrollment information.

Where is the NCT04556019 trial being conducted?

This trial is being conducted at Pamplona, Spain.

Who is sponsoring the NCT04556019 clinical trial?

NCT04556019 is sponsored by Fundacion Miguel Servet. The principal investigator is Francisco Javier Herrera Cabezón, MD at Complejo Hospitalario de Navarra. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology